Skip to main content

Breast Cancer - Male News

SABCS: Imlunestrant Tied to Improved PFS for ER-Positive, HER2-Negative Breast Cancer With ESR1 Mutations

THURSDAY, Dec. 12, 2024 – For patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer, imlunestrant leads to significantly...

U.S. Breast Cancer Deaths Keep Declining, Though Disparities Remain

TUESDAY, Oct. 1, 2024 – While women overall are less likely to die of breast cancer now, some alarming disparities remain, a new American Cancer Society (ACS) analysis warns. Death rates for...

FDA Approves Piqray (alpelisib) as First PI3K Inhibitor for Breast Cancer

May 24, 2019 -- Today, the U.S. Food and Drug Administration approved Piqray (alpelisib) tablets, to be used in combination with the FDA-approved endocrine therapy fulvestrant, to treat ...

FDA Approves Ibrance (palbociclib) for the Treatment of Men with HR+, HER2- Metastatic Breast Cancer

April 4, 2019 – Pfizer (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) to expand the indications for Ibrance...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Breast Cancer

Related drug support groups

tamoxifen, Ibrance